Seattle, WA, August 4, 2010 — TapImmune Inc. (OTCBB: TPIV) announced that it has signed a Research and Technology License Option Agreement with Mayo Clinic, Rochester, MN, for the development of a smallpox vaccine technology. Research will be conducted by Gregory Poland M.D., at Mayo Clinic, to evaluate novel peptide antigens together with TapImmune’s proprietary…Details
Bellevue, WA – June 1, 2010 — TapImmune Inc. (OTC BB: TPIV) announced that it has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo…Details
Bellevue, WA, May 24, 2010 — TapImmune Inc. (OTCBB: TPIV) announced today that the Company has completed the sale of Senior Secured Convertible Notes (“Notes”) totaling $1.53 million. As previously announced the net proceeds of the financing will be used for the development of partnerships for the clinical development of proprietary vaccine technologies and for…Details
TapImmune Inc. Executes A Securities Purchase Agreement For The Issuance Of $1.53 Million In Convertible Debt
Bellevue, Washington – May 18, 2010 — TapImmune Inc. (OTCBB: TPIV), a Nevada corporation, announced today that the Company entered into a definitive purchase agreement on May 17, 2010 with accredited investors to place Senior Secured Convertible Notes (collectively, “Notes”) totaling $1.53 million. The net proceeds of the financing will be used for the development…Details
Industry News Flash Dendreon receives FDA approval for Provenge – the first approved cancer vaccine.
The FDA has approved Dendreon’s Provenge, a breakthrough cancer vaccine that promises to extend the lives of prostate cancer victims by several months. The approval marks a transformative change for Dendreon, which is likely to vault into the top ranks of the world’s biotech companies as revenue from Provenge funds additional discovery work. Dr. Phillip…Details
Bellevue, WA – February 23, 2010 — TapImmune Inc. (OTCBB: TPIV), is pleased to provide this corporate update to our shareholders and other interested parties. With 2010 now out of the starting blocks, we would like to thank our shareholders for their continued support. Like most if not all companies, the 08/09 years were some…Details
TapImmune Inc. Signs R&D Collaboration Letter Of Intent Agreement With Aeras Global Tb Vaccine Foundation
– R&D Collaboration Will Evaluate the Efficacy of Various TB Vaccines at Aeras Facility in Rockville, MD – Bellevue, WA February 1, 2010 – TapImmune Inc. (OTCBB: TPIV) announced that it has signed a Letter of Intent (LOI) with Aeras Global TB Vaccine Foundation to enter into an R&D collaboration effort. The overall goal of…Details
Bellevue, WA — Taplmmune, Inc. (TPIV.OB) announced that it has retained Wolfe Axelrod Weinberger Associates LLC as its investor relations counsel to communicate its strategic goals and business opportunities in order to increase investor awareness and thereby enhance shareholder value. Denis Corin, President, stated, “Taplmmune has made significant strides recently and we believe that it…Details
Bellevue, WA — Taplmmune, Inc. (TPIV.OB) announced today President Denis Corin will be presenting at the OneMedPlace’s Forum 2010, Emerging Company Finance Conference, on Wednesday, January 13, 2010, at 9:15 a.m. Pacific time (12:15 p.m. Eastern time). The conference is being held at the Sir Francis Drake Hotel in San Francisco.
Bellevue WA, 25 November, 2009 – TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, within the last 60 days secured an additional $600,000 in equity funding, bringing the total for the last six months of 2009 to over $1,000,000. The recent investors acquired $.80…Details